LOS ANGELES


,


Dec. 2, 2022


/PRNewswire/ —


Glancy Prongay

& Murray LLP

(“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ:

EIGR

).

Class Period:


March 10, 2021

–

October 4, 2022



Lead Plaintiff Deadline:


January 9, 2023

If you wish to serve as lead plaintiff of the Eiger lawsuit, you can submit your contact information at

www.glancylaw.com/cases/eiger-biopharmaceuticals-inc/

. You can also contact

Charles H. Linehan

, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at

[email protected]

to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Defendants overstated Eiger’s clinical and regulatory drug development expertise; (2) Defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the peginterferon lambda EUA; (3) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (4) as a result, the FDA was unlikely to approve the submission of a peginterferon lambda EUA; (5) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on

LinkedIn

,

Twitter

, or

Facebook

.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact

Charles Linehan, Esquire

, of GPM, 1925 Century Park East, Suite 2100,

Los Angeles, California

90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to

[email protected]

, or visit our website at

www.glancylaw.com

. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay

& Murray LLP,

Los Angeles



Charles Linehan

, 310-201-9150 or 888-773-9224


[email protected]



www.glancylaw.com

View original content to download multimedia:

https://www.prnewswire.com/news-releases/eigr-investors-have-opportunity-to-lead-eiger-biopharmaceuticals-inc-securities-fraud-lawsuit-301692224.html

SOURCE

Glancy Prongay

& Murray LLP